Management of Primary Cicatricial Alopecias: Options for Treatment

    Matthew Harries, Rodney Sinclair, S. Macdonald-Hull, David Whiting, C.E.M. Griffiths, Ralf Paus
    Image of study
    TLDR There are many treatments for permanent hair loss disorders, but their effectiveness varies and there's no clear best option.
    The 15-year-old review article "Management of primary cicatricial alopecias: options for treatment" discussed the challenges and treatment options for primary cicatricial alopecias (PCAs), disorders causing permanent hair loss. The authors noted that PCAs are poorly understood and characterized by the replacement of follicular structures with scar-like fibrous tissue. The aim of treatment was to reduce symptoms and slow or stop the progression of the scarring process. Various treatments were discussed, including potent topical corticosteroids, intralesional triamcinolone acetonide, antimalarials, oral retinoids, thalidomide, griseofulvin, mycophenolate mofetil, low molecular weight heparin, and excimer laser. The effectiveness of these treatments varied, with some showing marked improvement in some patients, while others showed no response or even deterioration. The authors concluded that the overall level of evidence to support one form of treatment over another was low, and treatment preference was often based on the physician's personal experience, expected adverse effects, and pragmatic considerations.
    Discuss this study in the Community →

    Research cited in this study

    34 / 34 results

    Related Community Posts Join

    6 / 289 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  119 upvotes 6 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    4 / 4 results